Clinical Trial Update: To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet [Phase 1]

View source ↗

Summary

Completed Phase 1 pharmacokinetic study evaluating the impact of renal impairment on blood levels of a fixed-dose combination tablet containing daclatasvir, asu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED